[Whitepaper] Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Translational Pharmaceutics is defined as a process that integrates formulation development, real time adaptive manufacturing and clinical research, to efficiently advance key stages of the drug development. Fundamentally, Translational Pharmaceutics reduces the time between production and dosing from months to weeks and, given that decision-making is driven by human data, reduces the probability that a drug will fail in later stage clinical testing due to sub-optimal formulation performance. This approach streamlines the management of outsourcing partners through assignment of a single vendor and a cross functional project manager.

Download the white paper to learn more. 


Sponsored by: